Congenital Adrenal Hyperplasia (CAH) Therapeutic Market is segmented By Drug Type (Steroid Replacement Therapy, Non-Steroidal Therapies), By Route of Administration (Oral ....
Market Size in USD
CAGR5.8%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 5.8% |
Market Concentration | Medium |
Major Players | Diurnal Group plc, Spruce Biosciences, Inc., Neurocrine Biosciences, Inc., Millendo Therapeutics, Adrenas Therapeutics, Inc. |
The congenital adrenal hyperplasia (CAH) therapeutic market is estimated to be valued at USD 370.3 million in 2024 and is expected to reach USD 550 million by 2031, growing at a compound annual growth rate (CAGR) of 5.8% from 2024 to 2031. The market has seen steady growth in recent years and is expected to continue growing moderately over the forecast period due to increasing treatment rates and demand for specialized drugs to manage the condition.